Multiple drugs that target the IL-17 pathway are being investigated in clinical trials for various inflammatory diseases, and the first therapeutic antibody that inhibits IL-17 was approved for ...

Oruka Therapeutics, Inc. (NASDAQ:ORKA), a biopharmaceutical company specializing in diagnostic substances with a market ...